Prescient’s Dr. Anuj Gupta was quoted in an article in The Economic Times:
Sun Pharma is warming up to biosimilars. But complexity and competition make the business a gamble
While most leading pharma players in India kicked off their biosimilars programmes around a decade ago, Sun Pharma chose to sit out. However, founder Dilip Shanghvi recently announced that the company will be making a foray into this buzzing segment. What prompted the shift in strategy to explore a risky business?
Prescient Healthcare Group supported Incyte Biosciences Iberia in executing ImPATH (IMprove PATient PATHway in DLBCL), a project that engaged a multidisciplinary team of experts to assess the patient care pathway for DLBCL in Spain.
Here at Prescient, we’re excited to share a major step in our sustainability journey. After careful calculation of our 2022 greenhouse gas emissions from business travel and commuting, we partnered with ACT Commodities Group, a leading provider of market-based environmental solutions. With its support, we have successfully arranged to offset our carbon emissions by investing in a wind power project that will generate 44 MW of electricity from previously barren land in Maharashtra, India.
We are thrilled to announce that Strategic North, part of Prescient Healthcare Group, won the
San Francisco
+1 415 230 8460New York
+1 973 347 7750Boston
+1 857 341 0341Madrid
+34 919 34 7715Barcelona
+34 93 255 61 00Manchester
+44 161 942 9610London
+44 20 8832 7900Munich
+49 89 5419 8883New Delhi
+91 11 712 9170Beijing
+86 10 6562 9095
LinkedIn
Twitter
Facebook